Structural and functional properties of proteasomes purified from the human kidney

Journal of Nephrology

Volumn 19, Issue 6, 2006, Pages 710-716

  Baldovino, Simone ^a,b   Piccinini, Marco ^b   Anselmino, Annalisa ^b   Ramondetti, Cristina ^b   Rinaudo, Maria Teresa ^b   Costanzo, Piera ^a   Sena, Luigi M ^b   Roccatello, Dario ^a,b  

^a S GIOVANNI BOSCO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Human kidney proteasome; INF gamma inducible subunits; Peptidase activity; Two dimensional electrophoresis

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ENZYMATIC ASSAY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBUNIT; GEL ELECTROPHORESIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; PROTEIN FUNCTION; PROTEIN METABOLISM; WESTERN BLOTTING;

HUMANS; INFLAMMATION; KIDNEY CORTEX; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, QUATERNARY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 33947200383     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739-58.
2. Glickman MA, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
3. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20 and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-47.
4. Rock KL, Goldberg AL. Degradation of cell proteins and generation of MHC class I-presented peptides. Annu Rev Immunol 1999; 17: 739-79.
5. Preckel T, Fung-Leung WP, Cai Z, Vitiello A, Salter-Cid L, Winqvist O, Wolfe TG, Von Herrath M, Angulo A, Ghazal P, Lee JD, Fourie AM, Wu Y, Pang J, Ngo K, Peterson PA, Fruh K, Yang Y. Impaired immunoproteasome assembly and immune responses in PA28-/- mice. Science 1999; 286: 2162-5.
6. Noda C, Tanahashi N, Shimbara N, Hendil KB, Tanaka K. Tissue distribution of constitutive proteasomes, immunoproteasomes and PA28 in rats. Biochem Biophys Res Commun 2000; 277: 348-54.
7. Bochtler M, Ditzel L, Groll M, Hartmann C, Huber R. The proteasome. Annu Rev Biopbys Biomol Struct 1999; 28: 295-317.
8. Arendt CS, Hochstrasser M. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci U S A 1997; 94: 7156-6l.
9. Hallerlmalm K, Seki K, Wie C, Castelli C, Rivoltini L, Kiessling R, Levitskaya J. Tumor necrosis factor- induces coordinated changes in major histocompatibility class I presentation pathway, resulting in an increased stability of class I complexes at the cell surface. Blood 2001; 98: 1108-15.
10. Fru, K, Yang Y, Arnold D, Chambers J, Wu L, Waters JB, Spies T, Peterson PA. Alternative exon usage and processing of the major histocompatibility complex-encoded proteasome subunits. J Biol Chem 1992; 267: 22131-40.
11. Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-g-inducible proteasome activator PA28. Immunol Rev 1998; 163: 161-76.
12. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68: 1015-68.
13. Tanahashi N, Murakami Y, Minami Y, Shimbara N, Hendil KB, Tanaka K. Hybrid proteasomes: induction by interferon-gamma and contribution to ATP-dependent proteolysis. J Biol Chem 2000; 275: 14336-45.
14. Piccinini M, Tazartes O, Mostert M, Musso A, DeMarchi M, Rinaudo MT. Structural and functional characterization of 20S and 26S proteasome from bovine brain. Brain Res Mol Brain Res 2000; 76: 103-14.
15. Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F, Dianzani U, Tovo PA, Mostert M, Musso A, Rinaudo MT. Proteasomes are a target of the anti-tumor drug vinblastine. Biochem J 2001; 356: 835-41.
16. Piccinini M, Mostert M, Croce S, Baldovino S, Papotti M, Rinaudo MT. Interferon - inducible subunits are incorporated in human brain 20S proteasome. J Neuroimmunol 2003; 135: 135-40.
17. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Screiber SL. Inhibition of proteasome activities and subnnit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268: 726-31.
18. Claverol S, Burlet-Schiltz O, Girbal-Neuhauser E, Gairin JE, Monsarrat B. Mapping and structural dissection of human 20 S proteasome using proteomic approaches. Mol Cell Proteomics 2002; 1: 567-78.
19. Stohwasser R, Giesebrecht J, Kraft R, Muller EC, Hausler KG, Kettenmann H, Hanisch UK, Kloetzel PM. Biochemical analysis of proteasomes from mouse microglia: induction of immunoproteasomes by interferon-gamma and lipopolysaccharide. Glia 2000; 29: 355-65.
20. Wardle EN. Nuclear factor kappa for the nephrologist. Nephrol Dial Transplant 2001; 16: 1764-8.
21. Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, Mostert M, Tovo PA. The human 26S proteasome is a target of antiretroviral agents. AIDS 2002; 16: 693-700.
22. Zolfaghari R, Baker CR, Amirgholami A, Canizaro PC, Behal FJ. A multicatalytic high-molecular-weight neutral endopeptidase from human kidney. Arch Biochem Biophys 1987; 258: 42-50.
23. Hoffman L, Pratt G, Rechsteiner M. Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin/ATP-dependent proteases from rabbit reticulocyte lysate. J Biol Chem 1992; 267: 22362-8.
24. Piccinini M, Rinaudo MT, Anselmino A, Ramondetti C, Buccinna B, Fiano V, Ghimenti C, Schiffer D. Characterization of the 20S proteasome in human glioblastornas. Anticancer Res 2005; 25: 3203-10.
25. Bose S, Brooks P, Mason GGF, Rivett J. γ-Interferon decreases the level of 26S proteasomes and changes the pattern of phosphorylation. Biochem J 2001; 353: 291-7.
26. Groettrup M, Standera S, Stohwasser R, Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasorne. Proc Natl Acad Sci U S A 1997; 94: 8970-5.
27. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, Colbert RA. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 1998; 187: 97-104.
28. Hayashi T, Faustman D. The role of the proteasome in autoimmunity. Diabetes Metab Res Rev 2000; 16: 325-37.
29. Piccinini M, Mostert M, Rinaudo MT. Proteasomes as drug targets. Curr Drug Targets 2003; 4: 657-71.